Qbrexza was the largest of Journey Medical Corp’s 5 reported lines in fiscal 2025, at $25.01M — 41% of $61.24M.
| Product and Service | FY 2020 | FY 2021 | FY 2024 | FY 2025 |
|---|---|---|---|---|
| Targadox | — | — | ||
| Qbrexza | $25.11M | $25.01M | ||
| Qbrexa | — | — | ||
| Emrosi | — | $14.75M | ||
| Accutane | $19.41M | $12.88M | ||
| Ximino | — | — | ||
| Foam Franchise Products (Amzeeq Zilxi) | $6.65M | $5.86M | ||
| Exelderm | — | — | ||
| Other / Legacy | $3.96M | $2.74M | ||
| Other Branded Products | — | — | ||
| Total | $55.13M | $61.24M |
In fiscal 2025, which ended December 31, 2025, the 5 revenue lines Journey Medical Corp reported in this breakdown added up to $61.24M. The revenue lines reported changed from fiscal 2024, so the total is not directly comparable with the $55.13M reported that year. Qbrexza was the largest revenue line, at $25.01M or 40.8% of the total, followed by Emrosi ($14.75M, 24.1%) and Accutane ($12.88M, 21.0%). Together, the two largest revenue lines made up 64.9% of this total.
Compared with fiscal 2024, every sizeable revenue line reported in both years shrank. Qbrexza held up best, down 0.4% to $25.01M, while Accutane fell the most, down 33.6% to $12.88M. Because revenue lines were added or dropped between the two years, part of this reflects how Journey Medical Corp regrouped its reporting.
Emrosi was first reported as a separate revenue line in fiscal 2025. The table also keeps 5 revenue lines that Journey Medical Corp no longer reports, so earlier years can still be read on their original basis; use "Show 5 discontinued" beneath the table to see them. This breakdown covers 4 fiscal years between 2020 and 2025, as reported in Journey Medical Corp's annual filings.
Journey Medical Corp (DERM) breaks its revenue down by revenue line. In fiscal 2025, its largest revenue line was Qbrexza, with $25.01M or 40.8% of the total, followed by Emrosi at $14.75M (24.1%).
Qbrexza was Journey Medical Corp's largest revenue line in fiscal 2025, with $25.01M in revenue, 40.8% of the $61.24M reported across its 5 revenue lines.
Every figure is taken from Journey Medical Corp's annual financial filings and shown as reported: each line keeps the name the company gives it, years follow its own fiscal calendar, and lines it has stopped reporting stay in the table for the years they were reported.
The breakdown by revenue line covers fiscal 2020 to 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.